Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04555031
Other study ID # ROC2-20-012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2020
Est. completion date September 16, 2020

Study information

Verified date October 2021
Source Bausch & Lomb Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 20 habitual soft contact lens wearing participants will be enrolled in this unilateral, randomized, double-masked (participant and investigator masked) repeated measures insertion study. All participants will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If participants satisfy all eligibility criteria and none of the exclusion criteria, subjects will insert study lenses in random, successive order according to unique randomization schedules that will be provided to each Investigator.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date September 16, 2020
Est. primary completion date September 16, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older and have full legal capacity to volunteer. - Physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. - No active ocular disease or allergic conjunctivitis. - Not using any topical ocular medications. - Willing and able to follow instructions. - Signed a statement of informed consent. Exclusion Criteria: - Participating in a conflicting study in the opinion of the Investigator. - Considered by the Investigator to not be a suitable candidate for participation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
kalifilcon A lenses
Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Dalies Total 1
Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Precision 1
Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Biotrue ONEday
Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.

Locations

Country Name City State
United States Bausch and Lomb Site 01 Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Surface Refractive Index Shifts at 5 Minutes Refractive index is the ratio of velocity of light in a material divided with velocity of light in vacuum. The eye was measured for surface refractive index on the refractometer. The refractive index of a medium is the ratio of the speed of light in vacuum to the speed of light in the medium. It has no units. 5 minutes
Primary Surface Refractive Index Shifts at 10 Minutes Refractive index is the ratio of velocity of light in a material divided with velocity of light in vacuum. The eye was measured for surface refractive index on the refractometer. The refractive index of a medium is the ratio of the speed of light in vacuum to the speed of light in the medium. It has no units. 10 minutes
Primary Surface Refractive Index Shifts at 15 Minutes Refractive index is the ratio of velocity of light in a material divided with velocity of light in vacuum. The eye was measured for surface refractive index on the refractometer. The refractive index of a medium is the ratio of the speed of light in vacuum to the speed of light in the medium. It has no units. 15 minutes
See also
  Status Clinical Trial Phase
Completed NCT04840563 - Surface Refractive Index Shift and Lens Absorption/Adsorption of Tear Components of Kalifilcon A Lenses vs Dailies Total1 and Precision1 N/A